07:50 AM EDT, 03/19/2026 (MT Newswires) -- Eli Lilly ( LLY ) said Thursday that a phase 3 study of retatrutide in type 2 diabetes met its primary and all key secondary endpoints.

Participants in the study who took retatrutide had average A1C reductions of up to 2%, achieving the primary endpoint, while a key secondary endpoint achieved weight loss that averaged 36.6 pounds, the company said.

Eli Lilly ( LLY ) also said it expects additional results from the retatrutide clinical trial program over the next year.